Simon Amy

Chief Medical Officer Simon Amy sold 30.6K shares ($547.8K) at $17.92 average; stock down 51.7% from 52-week high, revenue collapsed 83.2% YoY.

Simon Amy, Chief Medical Officer at Beam Therapeutics, executed 2 separate sales totaling 30,563 shares for $547,835.45 on April 1–2, 2025, reducing his holdings by 31.7%. The sales occurred at a blended average price of $17.92, while the stock now trades at $16.46—51.7% below its 52-week high and 37.8% lower over the past 30 days. The company is unprofitable with net income of $-96,668,000.00 for its most recent full fiscal year, and quarterly revenue of $14,269,000.00 represents an 83.2% annual revenue decline. Critically, his prior 2 sales at BEAM were both well-timed at the 90-day mark (prior-year sales showed 90d returns of -24.5% and -27.1%), and his cross-ticker track record shows a 100.00% well-timed rate across all prior sales, with an average 90d return of -25.8%. The sale pattern—discretionary, material reduction of 31.7% of pre-transaction holdings, and execution amid deteriorating fundamentals and severe downward price momentum—warrants investor scrutiny of forward guidance and operational developments at Beam.